Basiliximab

Generic Name: Basiliximab

Brand Names: Simulect

Drug Type: Biotech

CAS Number: 179045-86-4

Unique Ingredient Identifier: 9927MT646M

Background: A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.

Indication: For prophylactic treatment of kidney transplant rejection

Associated Conditions: Rejection Acute Renal

Clinical Trials

Induction With SVF Derived MSC in Living-related Kidney Transplantation

Phase 1

Conditions: Living-relative Kidney Transplantation

Interventions: Drug: Basiliximab induction
Procedure: SVF-MSC induction

First Posted Date: 2015-07-08

Last Posted Date: 2015-07-08

Lead Sponsor: Fuzhou General Hospital

Target Recruit Count: 120

Registration Number: NCT02492308

Locations: 🇨🇳
Xi er huan road No.156, Fuzhou, Fujian, China

Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant

Phase 2

Completed

Conditions: Kidney Transplant
Type 1 Diabetes

Interventions: Drug: Alpha 1-Antitrypsin
Procedure: Islet Transplantation
Drug: Thymoglobulin
Drug: Basiliximab
Drug: Etanercept

First Posted Date: 2015-06-08

Last Posted Date: 2023-12-22

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 2

Registration Number: NCT02464878

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

The Usefulness of Tacrolimus Without Basiliximab in Well Matched Living Renal Transplantation in Korea

Not Applicable

Conditions: Kidney Transplantation

Interventions: Drug: No basiliximab
Drug: Basiliximab
Procedure: Kidney transplantation

First Posted Date: 2015-06-02

Last Posted Date: 2015-06-02

Lead Sponsor: Asan Medical Center

Target Recruit Count: 40

Registration Number: NCT02459977

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Simulect Versus ATG in Sensitized Renal Transplant Patient

Phase 4

Completed

Conditions: Renal Transplant Rejection

Interventions: Drug: Simulect
Drug: ATG Fresenius

First Posted Date: 2015-03-03

Last Posted Date: 2017-10-25

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 60

Registration Number: NCT02377193

Locations: 🇫🇷
UHToulouse, Toulouse, France

DC Migration Study for Newly-Diagnosed GBM

Phase 2

Completed

Conditions: Giant Cell Glioblastoma
Glioblastoma Multiforme
Astrocytoma, Grade IV
Glioblastoma

Interventions: Biological: Unpulsed DCs
Biological: Td
Biological: Human CMV pp65-LAMP mRNA-pulsed autologous DCs
Biological: 111In-labeled DCs
Drug: Temozolomide
Drug: Basiliximab
Drug: Saline

First Posted Date: 2015-02-19

Last Posted Date: 2023-06-08

Lead Sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP

Target Recruit Count: 64

Registration Number: NCT02366728

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation

Phase 4

Completed

Conditions: Liver Transplantation

Interventions: Drug: Basiliximab
Drug: Tacrolimus
Drug: Mycophenolic Acid

First Posted Date: 2014-04-25

Last Posted Date: 2022-09-29

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 59

Registration Number: NCT02123108

Locations: 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF

Phase 4

Terminated

Conditions: Kidney Transplantation

Interventions: Drug: Basiliximab treatment
Drug: Anti-Thymocyte Globulins treatment

First Posted Date: 2014-02-06

Last Posted Date: 2017-11-21

Lead Sponsor: Nantes University Hospital

Target Recruit Count: 19

Registration Number: NCT02056938

Locations: 🇫🇷
Nantes Universitary hospital, Nantes, France
🇫🇷
Universitary hospital of Lyon, Lyon, France
🇫🇷
Necker Hospital, Paris, France

and more 1 locations

Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Interventions: Drug: Basiliximab
Drug: Methylprednisolone
Drug: Prednisone
Drug: Tacrolimus
Drug: Mycophenolate mofetil

First Posted Date: 2013-06-24

Last Posted Date: 2017-11-06

Lead Sponsor: Emory University

Target Recruit Count: 31

Registration Number: NCT01884571

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States